About the Research Program
The Psychiatry Clinical Research Program at Ben Taub Hospital is dedicated to advancing the understanding and treatment of psychiatric and neuropsychiatric conditions. Our program conducts clinical trials and investigator-initiated research studies on mood disorders, psychotic disorders, substance use disorders, and more. Our research approaches include investigational therapeutics, neuroimaging, neurocognitive assessments, wearable technologies, and high-throughput data analysis – enabled by a committed team and an extensive network of commercial and academic collaborators.
Current Studies at a Glance
| Study and Treatment | Condition(s) | Brief Description |
|---|---|---|
| CRAVE Support Phone application | Opioid use disorder | 4-week study gathering data from individuals with OUD to explore the potential use of wearable devices in detecting and preventing opioid cravings. Compensation/payment for participation provided. Transportation to and from site provided. |
| KINECT-Next NBI-1065890 | Tardive dyskinesia | 10-12-week study evaluating the efficacy of NBI-1065890 Compensation/payment for participation provided. Transportation and meal stipends for subjects and caretakers are also provided. |
| AMPA – NOVA 1 NBI-1065845 | MDD | 12-14-week study of NBI-1065845 as an add-on to current antidepressants that have not fully worked. Compensation/payment for participation provided. Transportation and meal stipends are also provided. |
| AMPA – Vega 2 NBI-1065845 (long-term) | MDD | Long-term (up to ~3 years) open-label safety and tolerability study of NBI-1065845. Compensation/payment for participation provided. Transportation and meal stipends are also provided. |
| Norlight ACP-211 | MDD, TRD | 4-6-week study of ACP-211 as a standalone treatment for patients whose depression has not improved with at least 2 prior antidepressants. Compensation/payment for participation provided. Transportation and meal stipends are also provided. |
| OARS 7 Seltorexant/JNJ-42847922 | MDD with insomnia | Testing whether seltorexant, when added to current antidepressants, improves depression and sleep. Compensation/payment for participation provided. Transportation stipends are also provided. |
| 821P203 SPN-821 | MDD | 7-week study testing the efficacy of SPN-821 as an add-on to a current antidepressant regimen. Compensation/payment for participation provided. Transportation and meal stipends are also provided. |
Pending trials not yet listed here include two new MDD studies, two new ADHD studies, and two new Alzheimer’s Disease studies. Please contact us if you are interested in participating in a pending trial or if you would like more details about any of our active trials.
Not sure if you qualify? Please don’t disqualify yourself! Reach out and let us help. Even if you do not think you meet the participation criteria, there may still be a study that is right for you.
Interested in participating?
We are always looking for individuals interested in participating in our research studies. Whether you are living with a psychiatric condition, in recovery, or simply curious about participating in research, we encourage you to reach out. Your participation contributes to treatments that may help you and others in the future – and all studies provide compensation for your time.
Interested in collaborating?
Our site at Ben Taub Hospital offers extensive research infrastructure, a large and diverse patient population, and highly experienced personnel representing a broad range of psychiatric specialties and scholarly interests. We welcome inquiries from sponsors, CROs and academic collaborators.
Questions? Contact our office during business hours at 713-873-5145. Call or text us with after-hours inquiries at 346-266-8167.